RxDoctor Payments Data

Mahesh Bajaj

Springfield, MANPI 1649247537

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 389 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,219 and has fallen 93.9% since, to $136 in 2023.

$7,529in general payments, 2019–2025

Across 389 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Sanofi$737
  • CSL Behring$630
  • Novartis$615
  • Takeda Pharmaceuticals U.S.A., Inc.$300
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$7,40298%
  • Education$1272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →